ANEB · trading date Oct 8, 2026 · previous close $0.37 · source: Alpaca (IEX feed, not consolidated full-market data).
Key Financials
Revenue
—
Net income
-$8.48M
Total assets
$12.15M
Total liabilities
$487.7K
Stockholders' equity
$11.66M
Cash & equivalents
$11.63M
Operating income
-$9.22M
Operating cash flow
-$6.35M
Capital expenditures
—
Fiscal year 2025, via 10-K filed 2025-09-29.
A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
4.0%
Equity / assets
96.0%
CapEx / revenue
—
Operating cash flow / net income
0.75×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
Lakeway, TX 78734
C/O ANEBULO PHARMACEUTICALS, INC.
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:58 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.